<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182960</url>
  </required_header>
  <id_info>
    <org_study_id>1024.3</org_study_id>
    <nct_id>NCT02182960</nct_id>
  </id_info>
  <brief_title>Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers</brief_title>
  <official_title>An Open Two Way Cross Over Study to Relative Bioavailability of Ibuprofen Enantiomers After Single p.o. Administration of 200 mg Syrup (T) Compared With 200 mg Standard Brufen Sirup (R)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Pharmacokinetics (relative bioavailability), safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total area under the plasma drug concentration-time curve from time zero to infinity (AUC0-∞)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug plasma concentration (Cmax)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal rate constant (λz)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total area under the plasma drug concentration-time curve from time zero to the last quantifiable drug (AUC0-t(last))</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time, total (MRTtot)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma clearance divided by the systemic availability factor (CL/f)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during the terminal phase λz, divided by f (Vz/f)</measure>
    <time_frame>Up to 12 hours after each administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 8 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>Baseline, 8 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital functions (blood pressure and puls rate)</measure>
    <time_frame>Baseline, up to 8 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in standard laboratory evaluation</measure>
    <time_frame>Baseline, 8 days after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brufen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen syrup</intervention_name>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brufen syrup</intervention_name>
    <arm_group_label>Brufen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males from 21 to 50 years and within +-20% of their normal weight (Broca
             index)

          -  Written informed consent

        Exclusion Criteria:

          -  Any findings of the medical examination or laboratory tests deviating from normal and
             of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory (especially bronchial asthma and chronic
             obstructive pulmonary disease), cardiovascular, metabolic, immunological or hormonal
             disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of a drug with a long half-life (&gt;=24 hours) within at least one month or less
             than ten half-lives of the respective drug before enrolment in the study

          -  Use of any drugs which might influence the results of the trial within seven days
             prior to administration or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             the start of the study

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking on study days

          -  Alcohol abuse

          -  Drug abuse

          -  Blood donation (&gt;100 ml) within four weeks prior to administration

          -  Other disease or abnormality of clinical relevance

          -  Excessive physical activities within two weeks prior to administration or during the
             trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

